CR10583A - Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio - Google Patents

Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio

Info

Publication number: CR10583A
Authority: CR; Costa Rica
Prior art keywords: cyclopropylpenhylmethyl; glucopiranosil; indol; conveyors; inhibitors
Prior art date: 2006-07-27

Application number

CR10583A

Other languages

English (en)

Inventor

Nomura Sumihiro

Sakamaki Shigeki

Original Assignee

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-27

Filing date

2009-01-26

Publication date

2009-06-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-26 Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp

2009-06-05 Publication of CR10583A publication Critical patent/CR10583A/es

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
239000008103 glucose Substances 0.000 title 1
229910052736 halogen Inorganic materials 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CR10583A 2006-07-27 2009-01-26 Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio CR10583A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82060406P	2006-07-27	2006-07-27
US88617807P	2007-01-23	2007-01-23

Publications (1)

Publication Number	Publication Date
CR10583A true CR10583A (es)	2009-06-05

Family

ID=38515468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR10583A CR10583A (es)	2006-07-27	2009-01-26	Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio

Country Status (31)

Country	Link
US (1)	US7851617B2 (es)
EP (1)	EP2049557B1 (es)
JP (1)	JP5102294B2 (es)
KR (1)	KR101179312B1 (es)
CN (1)	CN101501053B (es)
AR (1)	AR062111A1 (es)
AT (1)	ATE501159T1 (es)
AU (1)	AU2007277662B2 (es)
BR (1)	BRPI0715369A2 (es)
CA (1)	CA2658116C (es)
CL (1)	CL2007002197A1 (es)
CO (1)	CO6150170A2 (es)
CR (1)	CR10583A (es)
DE (1)	DE602007013056D1 (es)
DK (1)	DK2049557T3 (es)
EA (1)	EA016819B1 (es)
GT (1)	GT200900014A (es)
HN (1)	HN2009000161A (es)
IL (1)	IL196267A0 (es)
JO (1)	JO2681B1 (es)
MX (1)	MX2009000995A (es)
MY (1)	MY145106A (es)
NO (1)	NO20085337L (es)
NZ (1)	NZ574072A (es)
PE (1)	PE20080522A1 (es)
PL (1)	PL2049557T3 (es)
PT (1)	PT2049557E (es)
TW (1)	TWI418556B (es)
UA (1)	UA92100C2 (es)
UY (1)	UY30506A1 (es)
WO (1)	WO2008013322A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ577391A (en) *	2006-12-04	2011-11-25	Janssen Pharmaceutica Nv	Thienyl-containing glycopyranosyl derivatives as antidiabetics
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2010002695A (es)	2007-09-10	2010-04-01	Janssen Pharmaceutica Nv	Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
ES2380408T3 (es)	2008-08-28	2012-05-11	Pfizer Inc.	Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
JP5658751B2 (ja)	2009-07-10	2015-01-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	１−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
EP2478357A1 (en) *	2009-09-15	2012-07-25	Janssen Pharmaceutica, N.V.	Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion
WO2011047113A1 (en) *	2009-10-14	2011-04-21	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
KR20120087950A (ko)	2009-10-20	2012-08-07	노파르티스 아게	글리코시드 유도체 및 그의 용도
US8669380B2 (en)	2009-11-02	2014-03-11	Pfizer Inc.	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
FR2969614A1 (fr) *	2010-12-28	2012-06-29	Sanofi Aventis	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
ES2612492T3 (es) *	2010-12-28	2017-05-17	Sanofi	Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
WO2012140120A1 (en)	2011-04-13	2012-10-18	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EP2712360B1 (en) *	2011-05-20	2017-04-12	Janssen Pharmaceutica NV	Process for the preparation of compounds useful as inhibittors of sglt-2
ES2638915T3 (es) *	2011-05-20	2017-10-24	Janssen Pharmaceutica, N.V.	Procedimiento de preparación de compuestos usados como inhibidores de SGLT-22
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013090550A1 (en) *	2011-12-15	2013-06-20	National Health Research Institutes	Novel glycoside compounds
AR097890A1 (es)	2013-10-17	2016-04-20	Lilly Co Eli	Compuestos de urea
AR098134A1 (es)	2013-11-01	2016-05-04	Lilly Co Eli	Compuestos de urea
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP7137318B2 (ja) *	2018-02-22	2022-09-14	オルガノ株式会社	被処理液の精製方法
CN115772163B (zh) *	2022-12-09	2025-07-22	中国科学院成都生物研究所	吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5731292A (en) *	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
US5830873A (en) *	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
ES2254376T3 (es)	2000-03-17	2006-06-16	Kissei Pharmaceutical Co., Ltd.	Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados.
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
SK287786B6 (sk)	2000-12-28	2011-09-05	Kissei Pharmaceutical Co., Ltd.	Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
EP1364957B1 (en)	2001-02-26	2008-12-31	Kissei Pharmaceutical Co., Ltd.	Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002068440A1 (en)	2001-02-27	2002-09-06	Kissei Pharmaceutical Co., Ltd.	Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da)	2001-04-11	2006-05-15	Bristol Myers Squibb Co	Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
EP1389621A4 (en) *	2001-04-27	2005-05-11	Ajinomoto Kk	N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
WO2003011880A1 (fr)	2001-07-31	2003-02-13	Kissei Pharmaceutical Co., Ltd.	Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030087843A1 (en) *	2001-09-05	2003-05-08	Washburn William N.	O-pyrazole glucoside SGLT2 inhibitors and method of use
US6562791B1 (en) *	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
DE10231370B4 (de) *	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
MXPA05000725A (es)	2002-08-09	2005-04-08	Taisho Pharma Co Ltd	Procedimiento para la produccion selectiva de aril-5-tio-??-d-aldohexopiranosidos.
WO2004019958A1 (ja)	2002-08-27	2004-03-11	Kissei Pharmaceutical Co., Ltd.	ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ATE510834T1 (de)	2003-03-14	2011-06-15	Astellas Pharma Inc	C-glykosid-derivate zur behandlung von diabetes
WO2005012243A2 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted indole-o-glucosides
EP1679965A4 (en) *	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
UA86042C2 (en) *	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
CN104109155A (zh) *	2003-08-01	2014-10-22	田边三菱制药株式会社	新颖化合物
AU2004261663A1 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
CA2549017A1 (en) *	2003-08-01	2005-02-10	Mona Patel	Substituted indazole-o-glucosides
CA2581922A1 (en)	2004-09-29	2006-04-06	Kissei Pharmaceutical Co., Ltd.	1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008050353A (ja) *	2006-07-27	2008-03-06	Mitsubishi Tanabe Pharma Corp	医薬組成物

2007
- 2007-07-11 TW TW096125166A patent/TWI418556B/zh not_active IP Right Cessation
- 2007-07-25 JO JO2007306A patent/JO2681B1/en active
- 2007-07-25 UY UY30506A patent/UY30506A1/es unknown
- 2007-07-26 PE PE2007000981A patent/PE20080522A1/es not_active Application Discontinuation
- 2007-07-26 AR ARP070103316A patent/AR062111A1/es unknown
- 2007-07-26 CL CL200702197A patent/CL2007002197A1/es unknown
- 2007-07-26 US US11/878,760 patent/US7851617B2/en not_active Expired - Fee Related
- 2007-07-27 WO PCT/JP2007/065213 patent/WO2008013322A1/en not_active Ceased
- 2007-07-27 PT PT07791887T patent/PT2049557E/pt unknown
- 2007-07-27 EA EA200970161A patent/EA016819B1/ru not_active IP Right Cessation
- 2007-07-27 CN CN2007800277313A patent/CN101501053B/zh not_active Expired - Fee Related
- 2007-07-27 KR KR1020097004110A patent/KR101179312B1/ko not_active Expired - Fee Related
- 2007-07-27 DE DE602007013056T patent/DE602007013056D1/de active Active
- 2007-07-27 DK DK07791887.8T patent/DK2049557T3/da active
- 2007-07-27 JP JP2009521499A patent/JP5102294B2/ja not_active Expired - Fee Related
- 2007-07-27 MX MX2009000995A patent/MX2009000995A/es active IP Right Grant
- 2007-07-27 MY MYPI20090277A patent/MY145106A/en unknown
- 2007-07-27 CA CA2658116A patent/CA2658116C/en not_active Expired - Fee Related
- 2007-07-27 EP EP07791887A patent/EP2049557B1/en active Active
- 2007-07-27 PL PL07791887T patent/PL2049557T3/pl unknown
- 2007-07-27 BR BRPI0715369-4A patent/BRPI0715369A2/pt not_active IP Right Cessation
- 2007-07-27 AT AT07791887T patent/ATE501159T1/de active
- 2007-07-27 AU AU2007277662A patent/AU2007277662B2/en not_active Ceased
- 2007-07-27 NZ NZ574072A patent/NZ574072A/en not_active IP Right Cessation
- 2007-07-27 UA UAA200901760A patent/UA92100C2/uk unknown
2008
- 2008-12-19 NO NO20085337A patent/NO20085337L/no not_active Application Discontinuation
- 2008-12-30 IL IL196267A patent/IL196267A0/en not_active IP Right Cessation
2009
- 2009-01-22 GT GT200900014A patent/GT200900014A/es unknown
- 2009-01-26 CR CR10583A patent/CR10583A/es unknown
- 2009-01-26 HN HN2009000161A patent/HN2009000161A/es unknown
- 2009-01-27 CO CO09006937A patent/CO6150170A2/es unknown

Also Published As

Publication number	Publication date
CL2007002197A1 (es)	2008-02-15
JO2681B1 (en)	2013-03-03
UA92100C2 (uk)	2010-09-27
DK2049557T3 (da)	2011-06-14
UY30506A1 (es)	2008-01-31
DE602007013056D1 (de)	2011-04-21
EA200970161A1 (ru)	2009-06-30
HN2009000161A (es)	2011-05-25
NO20085337L (no)	2009-04-24
PL2049557T3 (pl)	2011-07-29
KR101179312B1 (ko)	2012-09-03
WO2008013322A1 (en)	2008-01-31
PT2049557E (pt)	2011-05-05
US7851617B2 (en)	2010-12-14
CN101501053B (zh)	2012-10-03
NZ574072A (en)	2011-05-27
EP2049557B1 (en)	2011-03-09
JP5102294B2 (ja)	2012-12-19
BRPI0715369A2 (pt)	2013-06-18
AU2007277662A1 (en)	2008-01-31
CA2658116A1 (en)	2008-01-31
MX2009000995A (es)	2009-02-04
CN101501053A (zh)	2009-08-05
JP2009544693A (ja)	2009-12-17
CO6150170A2 (es)	2010-04-20
EP2049557A1 (en)	2009-04-22
CA2658116C (en)	2011-07-19
MY145106A (en)	2011-12-30
TWI418556B (zh)	2013-12-11
AU2007277662B2 (en)	2011-02-03
ATE501159T1 (de)	2011-03-15
AR062111A1 (es)	2008-10-15
EA016819B1 (ru)	2012-07-30
GT200900014A (es)	2010-02-09
TW200811149A (en)	2008-03-01
US20080027122A1 (en)	2008-01-31
KR20090040356A (ko)	2009-04-23
PE20080522A1 (es)	2008-06-13
IL196267A0 (en)	2009-09-22

Publication	Publication Date	Title
GT200900014A (es)	2010-02-09	Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.
CR10743A (es)	2009-06-05	Derivados de azaadamantano y metodos de uso de los mismos
BRPI0810524A2 (pt)	2014-10-21	Derivado de (aza)indol e uso do mesmo para propósitos médicos
BRPI0810522A2 (pt)	2014-10-21	Mimétricos diazo bicíclicos de smac e uso dos mesmos.
BRPI0720625A2 (pt)	2014-03-25	Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
CR10709A (es)	2009-07-14	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ATE415400T1 (de)	2008-12-15	Pyrazolopyridinderivate
FR20C1027I2 (fr)	2021-06-11	Derives de tiglien-3-one
BRPI0809346A2 (pt)	2014-10-07	Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BRPI0815811A2 (pt)	2015-02-18	Derivados de indol substituído e métodos de uso dos mesmos
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
EP4125244C0 (en)	2025-01-01	HASH BASED MULTIHOSTING
DE602005026867D1 (de)	2011-04-21	Entzündungshemmende indol-derivate
EP1731506A4 (en)	2009-12-09	5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
BRPI0813457A2 (pt)	2014-12-23	Composto de organoenxofre contendo halogênio e uso do mesmo
BRPI0812909A2 (pt)	2014-12-09	Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0821142A2 (pt)	2015-09-15	derivados heterocíclicos bicíclicos
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1957492T3 (da)	2011-02-28	Substituerede bicykliske pyrimidonderivater
BRPI0815373A2 (pt)	2015-02-10	Derivados de ciclo-hexeno e o uso dos mesmos como fragrâncias
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DK1740583T3 (da)	2009-10-19	Oxadiazolon-derivater som ppar-delta-agonister